Strong Pipeline Progress
Arvinas entered a data-rich period with multiple early-stage clinical readouts, including ARV-102, ARV-806, and ARV-027, along with promising preclinical data from ARV-393 and ARV-6723.
Promising ARV-102 Data
ARV-102 showed up to 90% LRRK2 reduction in healthy volunteers and 97% reduction in Parkinson's patients, indicating strong potential for treating neurodegenerative diseases.
Financial Stability
Arvinas reported cash, cash equivalents, and marketable securities of $787.6 million, providing financial and strategic flexibility into the second half of 2028.
Strategic Collaboration with Pfizer
Arvinas and Pfizer jointly selected a third party for the commercialization of vepdegestrant, with the goal of launching it if approved.